Program Ends (kind of)

It’s true, the day-long program has concluded.

But the new relationships you formed are just beginning!

If you go back to work and don’t keep in touch with the people you met, well, why’d you come in the first place?

Go. Cement relationships. Build your network of medical device professionals on whom you can rely.

Start with me:

You’re a 10x alumnus now! You can call me anytime, for anything.

I’m happy to know you.


• 2-hour reception and networking with our sponsors, speakers, and guests
• Two drink tickets, light food included


Can’t make the whole event but want to mingle and learn?

No problem, join us at a steep discount Thursday night for our keynote and reception – and still meet everyone we assembled!

We’d love to include you, if even for a little while.

Philip Low, 10 years after his Cambridge Declaration on Consciousness will discuss “The Neurotechnology Revolution is Here (and it’s not a zero-sum game)”

We’re excited (honored, actually) to welcome 2016 keynote speaker (10x Medical Device Conference, San Diego) Philip Low, PhD back to our stage.

As NeuroVigil Chairman, CEO & Founder, iBrain Inventor and Cambridge Declaration on Consciousness Author, Dr. Low will share his latest developments and what you can expect from the future of neurotechnology.

We’ll also have a “Fireside Chat” with Dr. Low on this, the tenth anniversary of his seminal work, the “Cambridge Declaration on Consciousness.”

What Does The Metaverse Have To Do With All This?

Kate is a futurist and transhumanist who seeks to harness technology to promote humans beyond current physical and mental limitations.

What role do medical devices play?

How to Fast-track Medtech Adoption Among Clinicians

Andrew will discuss how to change behaviors to become more agile, how to facilitate technology adoption, and integrate into legacy systems.

Surgical Robotics, Conversational AI, and the Future of Healthcare

Details to follow.

What Happens If You Miss The MDR Deadline?

Ice Cream Social (Very Important!)

No offense to our speakers, but this is my favorite part of every 10x.

Make your own sundae with all the toppings! Yay!

Is Your Digital Health Innovation Rife with IP Risk?

Innovating in the digital health space is especially risky when it comes to intellectual property.

Speaker Stephen Carter will show you where the risks are and what you can do to protect yourself.

Valuable for any digital health entrepreneur.

The Seven Deadly Software-as-Medical-Device Challenges

Jeff McBride joins Diarmuid for questions and answers after a short presentation. They explain,

“For a medical device to be successful it needs to fulfil three essential criteria. It must fill an unmet medical need, it must demonstrate clinical utility, and it must have the support and endorsement of key opinion leaders. Software, is no different.

Doctors and clinicians are essentially in the business of data acquisition. “”How long have you felt this way?”” “”Where does it hurt?”” “”Have you changed your lifestyle recently?”” Is there a family history of this condition?”” Not all medical devices contain software, and not all health-related software is a medical device.

Understanding the classification of your software product or idea is critical towards determining the success or failure of your start-up company. Development of Software as a Medical Device (SaMD) presents a number of challenges to budding medical technology entrepreneurs. These include a wide range of hurdles to overcome including, finance, investment, technology, hardware, procurement, regulatory, legal etc. etc. The SaMD entrepreneur needs to be a master of all of these, or so it would appear.

SaMD entrepreneurs will get insights into best practices for developing products and meeting the challenges they face. Potential investors can gain insight into the mindset of the SaMD world. Potential suppliers and vendors can discover the most suitable ways of interacting with SaMD companies. Most importantly, by applying a patient-outcome approach towards the successful deployment of novel medical technologies, everyone will empathise and understand the needs and benefits of a successful product journey from concept to market.”